The Serum Institute of India has been at the center of vaccine production for COVID-19. But as the second wave crashes down on the country, an export ban via the Indian central government has put the company in a tough spot, with CEO Adar Poonawalla even fleeing to London. SII is at a point where it no longer holds the promise of production monopoly, and must expand to newer geographies and technology to strengthen its position as a global biotech company. Story originally reported by Seema Singh. News clips sourced from NDTV. Music and editing by Sameer Rahat from Baqsa Studios. Psst share your feedback with us on podcast@the-ken.com